對企業內專利工程師,這次的IHPE專欄則討論一下營業秘密。另外,本期也討論了如何養成專利工程師,接連上期的專利的價值,本期則推出實例篇,讓讀著能夠更進一步了解。而在English Resources專欄,則介紹公平、合理且非歧視(Fair, Reasonable and Non Discriminatory terms,簡稱FRAND)在專利授權的爭議性。
by Charl Goussard - NAIP Legal Research and Jeffrey Chang - NAIP Editorial
Imagine a single product: the myriad technologies involved, the swarm of patent rights holders, and the sea of comparable, alternative technologies. With so many complex and conflicting issues, it seems unlikely that an easy to use, functional product can ever reach the consumer. Yet, cell phones have become everyday objects. Dozens of companies put out hundreds of models that can be used interchangeably (for the most part) with different networks across the globe. This has been the power of FRAND patent licenses.
For both local and global pharmaceutical companies, the forthcoming amendments to the Taiwan Patent Act are of utmost importance as they will include substantial changes that will affect the biomedical industry in Taiwan. The Taiwan Intellectual Property Office (TIPO) has invested significant amounts of time in reviewing the current Patent Act and proposed amendments in an effort to bring Taiwan’s patent laws in line with global trends. To hear industry opinions on the amendments, TIPO held a public hearing on February 25th, 2009.
本電子報所登載之文章皆受著作權之保護,歡迎全篇轉寄,但請尊重著作財產權,未經同意授權,請勿部分轉貼或節錄轉寄。
Copyright 2008 North America Intellectual Property Corp., All rights reserved.
新北市永和區福和路389號五樓 TEL: (02)8923-7350 FAX: (02)8923-7390 http://www.naipo.com